Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Improve Your Recognition & Treatment of Osteoporosis

  |  Issue: July 2018  |  

Dr. LiebowitzJason Liebowitz is a second-year fellow in rheumatology at Johns Hopkins University. He earned his MD from Johns Hopkins University Medical School and completed his residency at Johns Hopkins Bayview. He has been published in JAMA Internal Medicine, The American Journal of Medicine, Medical Humanities, The Baltimore Sun and MedPage Today.

References

  1. Hillier TA, Lui LY, Kado DM, et al. Height loss in older women: risk of hip fracture and mortality independent of vertebral fractures. J Bone Miner Res. 2012 Jan;27(1):153–159.
  2. Watson SL, Weeks BK, Weis LJ, et al. High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: The LIFTMOR randomized controlled trial. J Bone Miner Res. 2018 Feb;33(2):211–220.
  3. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov 1;357(18):1799–1809.

Related Articles

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…